Meet PSI at OCT DACH 2026!
PSI CRO is attending OCT DACH 2026 to discuss how sponsors can maintain operational control, enrollment predictability, and delivery confidence across global phase 2–3 programs.
Sponsors across the DACH region continue to face pressure around timelines, CRO oversight, and execution consistency across global studies. At OCT DACH 2026, PSI will be available to discuss practical approaches to improving trial predictability through operational rigor, site engagement, and AI-enabled feasibility and site intelligence.
PSI delivers 95% of First Patient In milestones and 97% of Last Patient In milestones on time across global programs, supported by proprietary platforms including INTELIA™, PSI’s AI-augmented trial management platform suite.
Attending team members:
-
Michael Sommer
Senior Director, Business Development
Related Resources:
Blog: The site economy: Understanding site decision-making
Webinar: Agentic AI in Clinical Trials — Swiss Biotech Day Panel
White Paper: The operational reality of agentic AI in phase 2-3 trials
